IN8bio, Inc. Files 8-K Report
Ticker: INAB · Form: 8-K · Filed: Jun 3, 2024 · CIK: 1740279
| Field | Detail |
|---|---|
| Company | In8bio, Inc. (INAB) |
| Form Type | 8-K |
| Filed Date | Jun 3, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-filing, 8-K, financials
TL;DR
IN8BIO filed an 8-K on 6/3/24 covering other events and financials.
AI Summary
On June 3, 2024, IN8bio, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits." The company, formerly known as Incysus Therapeutics, Inc., is incorporated in Delaware and headquartered in New York.
Why It Matters
This 8-K filing serves as an official notification of significant corporate events or financial updates for IN8bio, Inc., providing transparency to investors and the public.
Risk Assessment
Risk Level: low — This filing is a routine corporate disclosure and does not appear to contain immediate negative or positive news that would significantly alter the company's risk profile.
Key Numbers
- 001-39692 — SEC File Number (Identifies the specific filing for IN8bio, Inc.)
Key Players & Entities
- IN8BIO, INC. (company) — Registrant
- Incysus Therapeutics, Inc. (company) — Former Company Name
- June 3, 2024 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- New York (location) — Principal Executive Offices City
- 001-39692 (identifier) — SEC File Number
FAQ
What is the primary purpose of this 8-K filing for IN8bio, Inc.?
The filing is for "Other Events" and "Financial Statements and Exhibits," indicating it's a report of significant corporate activities or financial updates.
When was this 8-K report filed by IN8bio, Inc.?
The report was filed on June 3, 2024.
What was IN8bio, Inc.'s former company name?
IN8bio, Inc. was formerly known as Incysus Therapeutics, Inc.
In which state is IN8bio, Inc. incorporated?
IN8bio, Inc. is incorporated in Delaware.
What is the address of IN8bio, Inc.'s principal executive offices?
The principal executive offices are located at 350 5th Avenue, Suite 5330, New York, New York 10118.
Filing Stats: 448 words · 2 min read · ~1 pages · Grade level 10.9 · Accepted 2024-06-03 08:53:31
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share INAB The Nasdaq
Filing Documents
- d777605d8k.htm (8-K) — 25KB
- d777605dex991.htm (EX-99.1) — 23KB
- g777605g0601072217216.jpg (GRAPHIC) — 2KB
- 0001193125-24-152493.txt ( ) — 181KB
- inab-20240603.xsd (EX-101.SCH) — 3KB
- inab-20240603_lab.xml (EX-101.LAB) — 18KB
- inab-20240603_pre.xml (EX-101.PRE) — 11KB
- d777605d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release, dated June 3, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. IN8bio, Inc. Date: June 3, 2024 By: /s/ Patrick McCall Patrick McCall Chief Financial Officer and Secretary (Principal Financial and Accounting Officer)